Primary gallbladder malignancies represent aggressive hepatobiliary neoplasms with notoriously dismal outcomes. Among these clinical presentations, a gallbladder MiNEN stands out as an exceedingly rare diagnostic entity. Clinicians define mixed neuroendocrine-non-neuroendocrine neoplasms by the coexistence of distinct neuroendocrine and non-neuroendocrine components. Each histological lineage must comprise at least thirty percent of the viable tumor mass. Because early symptoms mimic benign cholelithiasis, physicians frequently encounter diagnostic uncertainty during initial evaluations. Recent clinical documentation highlights a remarkable case involving a young woman treated successfully in a low-resource environment. Understanding this distinct clinicopathological entity allows clinicians to optimize diagnostic triage and refine surgical management.

Understanding Gallbladder MiNEN Pathogenesis

Normal gallbladder mucosa completely lacks neuroendocrine cells, which makes the emergence of neuroendocrine neoplasms biologically intriguing. Consequently, investigators propose several compelling theories to explain how dual differentiation arises within a solitary gallbladder tumor. Most researchers support a monoclonal origin hypothesis where a single totipotent stem cell undergoes divergent differentiation during carcinogenesis. Alternatively, chronic mucosal irritation caused by longstanding cholelithiasis can induce intestinal or gastric metaplasia. This prolonged inflammatory transformation subsequently fosters neuroendocrine proliferation alongside classical epithelial dysplasia. Furthermore, modern genomic profiling reveals shared driver mutations between both histological components, including alterations in TP53 and KRAS. Therefore, molecular data strongly reinforce the monoclonal theory rather than two independent collision tumors arising simultaneously. In addition, the biological behavior and metastatic trajectory typically mirror the aggressiveness of the higher-grade neuroendocrine component. Because high-grade neuroendocrine carcinomas exhibit rapid proliferation, early vascular invasion and lymphatic spread frequently occur. Nevertheless, when clinicians achieve early diagnosis prior to distant dissemination, complete surgical resection confers durable survival. Understanding these pathogenic mechanisms remains indispensable for refining individualized clinical interventions.

Clinical Presentation and Diagnostic Workup

Patients harboring these rare mixed neoplasms usually present with insidious, non-specific symptoms that mimic common biliary conditions. For example, right hypochondrial discomfort, anorexia, early satiety, and progressive weight loss represent typical complaints. In more advanced presentations, abdominal palpation may reveal a firm right upper quadrant mass or localized tenderness. Clinicians rely heavily on modern cross-sectional imaging to differentiate aggressive malignancy from chronic cholecystitis. Ultrasonography generally identifies irregular gallbladder wall thickening or a polypoid intraluminal mass exceeding one centimeter. Furthermore, contrast-enhanced computed tomography accurately defines hepatic parenchymal invasion, biliary ductal involvement, and periportal lymphadenopathy. Magnetic resonance cholangiopancreatography provides superior visualization of vascular structures within the hepatoduodenal ligament. However, preoperative imaging modalities cannot reliably distinguish mixed neuroendocrine tumors from conventional adenocarcinoma. Consequently, clinicians must maintain a high index of clinical suspicion when cross-sectional imaging identifies suspicious polypoid lesions accompanied by lymph node enlargement. Surgeons should avoid percutaneous needle biopsies whenever resectability is feasible to minimize potential tumor seeding along the biopsy tract.

Histopathological Confirmation and Staining

A definitive diagnosis requires exhaustive microscopic evaluation and immunohistochemical validation by an expert surgical pathologist. Macroscopically, these tumors typically form polypoid or ulcerated masses invading the gallbladder wall. Microscopically, the lesion features two distinct morphologic components arranged in separate nests, sheets, or glandular architectures. The diagnostic consensus requires that both the neuroendocrine and non-neuroendocrine components comprise at least thirty percent of the viable neoplasm. Furthermore, pathologists perform specialized immunohistochemical staining to corroborate the diagnosis definitively. The neuroendocrine component demonstrates strong cytoplasmic immunoreactivity for synaptophysin, chromogranin A, and INSM1. Simultaneously, the non-neuroendocrine adenocarcinoma component displays robust positivity for cytokeratins such as CK7 and carcinoembryonic antigen. In addition, assessing the Ki-67 proliferation index remains mandatory because it classifies tumor grade and dictates prognostic expectations. Accurate grading separates well-differentiated neuroendocrine tumors from highly aggressive small cell or large cell neuroendocrine carcinomas. Accordingly, thorough histological examination prevents misclassifying mixed tumors as simple poorly differentiated adenocarcinomas, which ensures appropriate clinical staging and management.

Surgical Resection and Regional Clearance

Complete surgical resection represents the cornerstone of curative therapy for localized gallbladder neoplasms. However, surgical strategy must align with tumor invasion depth and nodal status. In early or localized presentations, open cholecystectomy combined with regional lymphadenectomy provides excellent locoregional disease control. Conversely, when tumors breach the muscular layer, surgeons perform extended radical cholecystectomy. This procedure includes non-anatomical wedge resection of liver segments IVb and V alongside meticulous lymph node dissection along the hepatoduodenal ligament. Surgeons must handle the gallbladder with extreme precision to avoid accidental iatrogenic perforation during mobilization. Bile spillage markedly elevates the danger of peritoneal dissemination and port-site recurrence. In the documented case, open cholecystectomy with regional lymphadenectomy achieved clear surgical margins and removed suspicious periportal nodes successfully. Consequently, the patient achieved long-term disease-free survival without early recurrence. Therefore, adhering to fundamental oncological principles during surgical extirpation delivers meaningful survival benefits even in complex presentations. Careful intraoperative evaluation and complete lymphatic clearance remain critical determinants of overall surgical success.

Systemic Therapy and Low-Resource Considerations

Administering systemic therapy for mixed neoplasms remains complex because randomized controlled clinical trials do not exist. Generally, medical oncologists direct systemic chemotherapy toward the more aggressive morphological component. For example, clinicians utilize platinum-etoposide regimens when high-grade neuroendocrine carcinoma dominates the histology. Conversely, when the adenocarcinoma component demonstrates greater invasiveness, fluoropyrimidine-based regimens or gemcitabine combinations serve as frontline choices. In low-resource healthcare settings, however, financial limitations and drug unavailability often restrict access to adjuvant chemotherapy. In addition, advanced molecular testing and targeted immunotherapies remain out of reach for many patients in underserved regions. Nevertheless, disciplined surgical technique can achieve durable disease control independently when teams secure negative margins. The index report demonstrated twelve months of recurrence-free survival following complete resection without adjuvant systemic chemotherapy. Thus, close surveillance using routine physical examinations, basic laboratory tests, and periodic abdominal ultrasound offers a viable alternative strategy. Ultimately, maximizing surgical precision and maintaining vigilant postoperative follow-up allows clinicians to navigate resource limitations and protect patient outcomes effectively.

Frequently Asked Questions

What defines a gallbladder MiNEN on pathological examination?

Pathologists define a mixed neuroendocrine-non-neuroendocrine neoplasm by the morphological presence of both neuroendocrine and non-neuroendocrine epithelial components. Crucially, each component must constitute at least thirty percent of the total tumor volume. The non-neuroendocrine portion typically manifests as classic adenocarcinoma, whereas the neuroendocrine portion usually represents high-grade small cell or large cell carcinoma. Furthermore, immunohistochemical markers such as synaptophysin, chromogranin A, and INSM1 validate neuroendocrine differentiation definitively.

What is the recommended surgical management for gallbladder MiNEN?

Complete surgical resection with negative margins provides the only reliable curative option for localized disease. Surgeons typically perform an open or laparoscopic cholecystectomy combined with an en bloc hepatic wedge resection of segments IVb and V. In addition, thorough regional lymphadenectomy encompassing the hepatoduodenal ligament remains vital for accurate staging. Meticulous surgical clearance prevents early locoregional recurrence and provides long-term survival benefits even without adjuvant systemic chemotherapy in selected patients.

When should clinicians consider adjuvant chemotherapy for these tumors?

Clinicians consider adjuvant chemotherapy based on surgical margins, pathological stage, and the dominant histological component. Because high-grade neuroendocrine carcinoma components carry significant metastatic risk, oncologists frequently administer platinum-based chemotherapy such as cisplatin and etoposide for advanced presentations. Conversely, when adenocarcinoma features predominate or lymph node involvement occurs, fluoropyrimidine-based or gemcitabine combinations are selected. Multidisciplinary teams tailor therapy individually to optimize tolerability and enhance overall systemic control.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Farhan M et al. Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Gallbladder. A Case Report From a Low-Resource Setting. Clin Case Rep. 2026 Oct undefined. doi: 10.1002/ccr3.73652. PMID: 42819606.

Frizziero M, Chakrabarty B, Nagy B, et al. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. Cancers (Basel). 2020;12(2):416. doi:10.3390/cancers12020416.

Delgado C, Cobb W, Dobrie L, Kuo E, Rosales A. Mixed Neuroendocrine Non-Neuroendocrine Neoplasm of the Gallbladder. ACS Case Reviews in Surgery. 2025;5(1):34-39.